期刊文献+

系统性红斑狼疮患者血脂异常相关性分析 被引量:2

Analysis of Correlation between Systemic Lupus Erythematosus Patients with Dyslipidemia
下载PDF
导出
摘要 目的:探究系统性红斑狼疮(Systemic Lupus Erythematosu,SLE)患者血脂异常的相关性。方法:选取148例SLE患者作为观察组,选取同期50例健康体检者作为对照组,观察比较两组患者血脂水平,包括总胆固醇(TC)、高密度脂蛋白-胆固醇(HDL-C)、甘油三酯(TG)以及低密度脂蛋白-胆固醇(LDL-C)等。按照是否使用激素分为使用激素组(57例)和未使用激素组(91例),根据狼疮肾炎(LN)诊断标准分为LN组(69例)与非LN组(79例),比较使用激素者和未使用激素者、LN组和非LN组患者血脂水平。结果:SLE患者TC、TG及LDL-C水平均显著高于对照组,而HDL-C水平低于对照组。使用激素组患者TC、TG水平均高于未使用激素组,且HDL-C水平更低,差异具有统计学意义(P<0.05),但组间LDL-C水平比较差异无统计学意义(P>0.05)。结论:SLE患者血脂水平出现明显异常,较健康者更易发生粥样硬化,且长时间使用激素者与LN患者出现血脂异常的概率更高,因此SLE的血脂异常现象与使用激素、LN呈正相关。 Objective:To explore the systemic lupus erythematosus(systemic lupus erythematosu,SLE)patient correlation analysis of dyslipidemia.Methods:148cases of SLE patients as the observation group,remember.Then selected the same period of 50 cases of healthy people were used as control group.Observation on blood lipid levels in the two groups included the total cholesterol(TC),triglyceride(TG),high density lipoprotein cholesterol(HDL-C)and low density lipoprotein cholesterol(LDL-C)etc.The use of hormone and comparison of 148 cases of SLE patients and was not used hormone,lupus nephritis(LN)group and non LN group,serum lipid levels.Results:The patients with SLE TC,TG and LDL-C levels were significantly higher than those in the control group,while the HDL-C level was lower than that of control group.The use of hormone in blood lipid group and the LN group showed more obvious abnormal condition.Conclusion:SLE patients will appear obvious abnormal lipid levels,more easily than healthy atherosclerosis.And the long time use of hormone and LN patients with abnormal blood lipid,therefore,SLE will not abnormal blood lipid and hormone use,LN is positive correlation.
作者 周铁
出处 《亚太传统医药》 2015年第8期68-70,共3页 Asia-Pacific Traditional Medicine
关键词 系统性红斑狼疮 血脂异常 狼疮肾炎 激素 相关性 Systemic Lupus Erythematosus Blood Lipid Disorder Lupus Nephritis Hormone Correlation
  • 相关文献

参考文献12

二级参考文献108

  • 1杨华夏,吕玮,范洪伟,刘晓清,李太生.系统性红斑狼疮合并中枢神经系统结核感染11例临床分析[J].中华临床医师杂志(电子版),2011,5(22):6603-6607. 被引量:3
  • 2刘力生.中国高血压防治指南2010[J].中国医学前沿杂志(电子版),2011,3(5):42-93. 被引量:1221
  • 3中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5227
  • 4Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine (HCQ) in lupus pregnancy:double blind and placebo-controlled study [ J ]. Lupus,2001,10:401-404.
  • 5Clowse ME, Magder L, Witter F, et al. Hydroxyehloroquine in lupus pregnancy[ J]. Arthritis Rheum, 2006,54:3640-3647.
  • 6Miyakis S, Lockshin MD, Atsumi T,et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome ( APS ) [ J ]. J Thromb Haemost, 2006,4 : 295-306.
  • 7Cunningham FG, Leveno K J, Bloom SL, et al. Williams obstetrics[ M]. 22st ed. NewYork : McGraw-Hill. 2005.
  • 8Bertsias G ,Ioannidis JP, Boletis J, et al. EULAR recommendatiors for the management of systemic lupus erythem-atosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics [ J ]. Ann Rheum Dis, 2008,67 : 1.
  • 9Cortes-Hernandez J, Ordi-Ros J, Paredes F, et at. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies [ J]. Rheumatology ,2002,41:643-650 .
  • 10Smyth A, Oliveira GH, Lahr BD, et al. A systematic review and metaanalysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis [ J ]. Clin J Am Soc Nephrol, 2010,5:2060-2068 .

共引文献57

同被引文献49

  • 1Sarkissian T, Beyenne J, Feldman B , et al. The complex nature of the interaction between disease activity and therapy on the lipid profile in patients with pediatric systemic lupus erythematosus[ J]. Arthrities Rheum,2006,54 (4) : 1283 - 1290.
  • 2Ettinger WH, Goldberg AP, Applebaum Bowden D, et al. Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids[ J]. Am J Med,1987,83(3) :503 -508.
  • 3Svens0n KL, Lundqvist G, Wide L, et al. Impaired glucose handling in active rheumatoid arthritis, effects of corticosteroids and antirheumatic treatment [J ]. Metabolism, 1987,36 ( 10 ) - 944 - 948.
  • 4Petri M. Detection of coronary artery disease and the role of tradi- tional risk factors in the Hopkins Lupus Cohort [ J ] Lupus,2000,9 (3) :170 - 175.
  • 5Bazzan M, Vaccarino A, Marletto F. Systemic lupus erythematosus and thrombosis[ J]. Thromb J ,2015,13 : 16.
  • 6Skaggs B J, Hahn BH, McMahon M. Accelerated atherosclerosis in patients with SLE - mechanisms and management [ J ]. Nat Rev Rheumatol,2012,8 (4) : 214 - 223.
  • 7Pego - Reigosa JM, Rua - Figueroa l, Lopez - Longo FJ, et al. Analysis ,of disease activity and response to treatment in a largeSpanish cohort of patients with systemic lupus erythematosus[ J ]. Lupus,2015,24 (7) :720 - 729.
  • 8Sinieato NA, da Silva Cardoso PA, Appenzeller S. Risk factors in cardiovascular disease in systemic lupus erythematosus [ J ]. Curr Cardiol Rev,2013,9( 1 ) :15 -19.
  • 9PanaroUn D, Remillard P, Rouffard L, et al. Insulin resistance affects the regulation of lipoprotein lipase in the postprandial period and in an adipose tissue speeitfic manner [J]. Eur J Clin Invest, 2002,32(2) :84 -92.
  • 10Gazareen S, Fayez D, El - Najjar M, et al. Study of insulin resist- ance in patients with systemic lupus erythematosus and rheumatoid arthritis [ J ]. Menoufia Medical Journal,2014,27 ( 2 ) :215 - 225.

引证文献2

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部